Dongyang Pharmaceutical (06887): Degumendong double insulin injection obtained marketing approval from China National Drug Administration

Zhitong Finance App News, Dongyangyang Pharmaceutical (06887) issued an announcement. The Degumendong double insulin injection independently developed by the Group has been officially approved for marketing by the China National Drug Administration (NMPA), covering both types of refills and pre-filled injection pens.

Tokugamendong double insulin injection is a double insulin analogue. It consists of 70% of basic Tokugai insulin and 30% of quick-acting meal-time Mondongan insulin in a fixed ratio of 7:3. The two components are independent and stable, and their activity does not interfere with each other. (1) Tokugu insulin has an ultra-long effect and stable release, with no significant peak in 24 hours, and stable control of fasting and baseline blood sugar; Mendong insulin works quickly and effectively suppresses the peak of blood sugar after meals. A single preparation can simultaneously control blood sugar on an empty stomach and after meals, significantly improving blood sugar fluctuations throughout the day, and improving the compliance rate of glycated hemoglobin. It is superior to traditional premixed insulin. (2) This product is a soluble preparation, which is easy to operate, supports flexible administration 1-2 times a day, greatly streamlines the treatment process, reduces the number of injections, effectively reduces the burden of medication use on patients, and enhances long-term treatment compliance. (3) It can be used not only for patients treated for the first time with insulin, but also for patients with type 2 diabetes with poor blood sugar control, high fluctuations, frequent hypoglycemia, and intolerance to multiple injections with traditional insulin. It can meet the individualized sugar reduction needs of different patients.

With the approval for marketing of Tokumendong's insulin injections, the number of insulin products approved by the Group in the Chinese market has increased to 7, creating a full range of insulin product matrices covering the second to fourth generation, covering the three major clinical application scenarios of basic, meal time and premixing.

In terms of research and pipeline, the Group's ultra-long-lasting insulin weekly formulation, HEC-151, has entered phase 1 clinical trial. In the future, it will form a multi-level product echelon of “daily formulations — weekly formulations — compound formulations” with already marketed products to achieve continuous iterative upgrading of the insulin product pipeline.

In terms of internationalization, the glycine insulin injection independently developed by the Group obtained an approval letter from the US Food and Drug Administration at the end of April 2026, making it the 4th glargine insulin product to be marketed in the US. At the same time, the company became the first Chinese pharmaceutical company to market insulin glargine in the US market. In the future, the Group will continue to promote overseas registration of various insulin products such as Modong insulin and Tokugai insulin, continue to promote the global layout of insulin products, expand international market share, enhance the international operation capability and brand influence of enterprises, and promote insulin products independently developed by China to the world, benefiting diabetics around the world.